Recent commentaries in the New York Times and Forbes lament the slow adoption by oncologists of a method of administering chemotherapy that’s been shown in several randomized controlled trials to improve survival in women afflicted with ovarian cancer.
David Scott Miller, M.D.
August 7, 2015
